Begin with the ingredient.
Semaglutide is a lab-made version of a gut hormone. It acts at GLP-1 receptors, the parts of cells that receive that hormone’s signals. Those signals are involved in appetite and blood sugar. That describes the medicine’s action; it cannot tell us whether it belongs in your care.
You may know semaglutide as the ingredient in the FDA-approved brand medicines Ozempic and Wegovy. That approval does not cover compounded semaglutide, which is not FDA-approved.
The preparation matters.
FDA-approved semaglutide products exist. Approval is for a particular product and use. It does not follow an ingredient into every preparation that contains it.
Compounding means preparing a medicine to meet a particular patient’s needs. Compounded semaglutide is not FDA-approved. A prescription and a pharmacy’s legal ability to prepare that prescription are separate questions. A provider’s review does not remove the pharmacy’s responsibilities.
Give the risks some room.
Nausea, vomiting, diarrhea and constipation appear in the approved medicine’s safety information. More serious concerns include gallbladder problems and inflammation of the pancreas, an organ involved in digestion and blood sugar.
The approved labels also carry a boxed warning, the FDA’s strongest warning, about thyroid tumors seen in rodents. Whether this happens in people is unknown. This short introduction is not the full safety information. A personal and family health history belongs in a provider’s review.
A few questions to take along.
- Which preparation are we discussing, and what is its approval status?
- How do my health history and other medicines affect the decision?
- What follow-up and help with side effects would be available?
There is no need to turn a first reading into a decision. Our weight and peptides guide puts semaglutide beside the broader questions. The tirzepatide guide explains another ingredient without ranking it for your health.